Fate Therapeutics (FATE) Misses Q3 EPS by 2c, Beats on Revenues

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $1 million versus the consensus estimate of $930 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Accenture downgraded by TD Cowen on AI concerns